Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events + Presentations
Environment, Social, and Governance
Media Library
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events + Presentations
Environment, Social, and Governance
Media Library
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
LinkedIn
Twitter
Scientific & Medical Presentations
WORLDSymposium 2023
Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease
WORLDSymposium 2023
Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease
ASH 2022
Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A
ASH 2022
Interim Safety and Efficacy Results From a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)
Prion 2022
ZF-transcription factors for Prion Disease
NORD 2022
Preliminary results of STAAR, a Phase I/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up
ESGCT 2022
Preliminary results of STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease and long term follow up
ESGCT 2022
Engineering of Allogeneic Regulatory T Cells Expressing a Chimeric Antigen Receptor (Allo-CAR-Tregs) Using Zinc Finger Nuclease/AAV6-Mediated Editing
ESGCT 2022
Engineering of Factor IX-secreting B cells using ZF-Nuclease / AAV6 editing technology in a GMP-compatible medium
SSIEM 2022
Preliminary results of STAAR, a Phase I/II study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease and long-term follow-up
ASGCT 2022
Engineered AAV Capsids Exhibit Improved Transduction of the Central Nervous System After CSF Administration in Adult Cynomolgus Macaques
ASGCT 2022
A Compact Zinc Finger Architecture for Highly Efficient Base Editing in Human Cells
ASGCT 2022
STEADFAST: A First-in-Human Study Assessing HLA-A*02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation
ASGCT 2022
Evaluation of a Human Neurovascular Model to Complement a Parallel Non-human Primate Selection for Blood–Brain Barrier Penetrant AAV Capsids
ASGCT 2022
Zinc Finger Nuclease/AAV6-Mediated Factor IX(FIX) Insertion Into B Cells Results in Sustained Therapeutic FIX Levels In Vivo After Using a GMP-Like Differentiation Culture System
ASGCT 2022
Genome Orthogonal Zinc Finger Proteins for the Development of Genomic Medicines
ASGCT 2022
Engineering of Allogeneic Regulatory T Cells Expressing a Chimeric Antigen Receptor(Allo-CAR-Tregs) Using Zinc Finger Nuclease/AAV6-Mediated Editing
ASGCT 2022
Durable, Multiplexed Cell Engineering Using Zinc Finger–Guided Transcriptional Regulators Delivered via a Single Viral Particle
WORLDSymposium 2022
Preliminary Results of the STAAR Study, a Phase I/II Study of Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults With Fabry Disease
ASH 2021
Preliminary Safety and Efficacy Results from PRECIZN-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD)